These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 21289267)

  • 1. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway.
    Liu R; Liu D; Trink E; Bojdani E; Ning G; Xing M
    J Clin Endocrinol Metab; 2011 Apr; 96(4):E577-85. PubMed ID: 21289267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
    Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
    Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
    Narayan RS; Fedrigo CA; Brands E; Dik R; Stalpers LJ; Baumert BG; Slotman BJ; Westerman BA; Peters GJ; Sminia P
    BMC Cancer; 2017 Mar; 17(1):204. PubMed ID: 28320338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional characterization of PI3K C2 domain mutations detected in breast cancer circulating tumor cells and metastatic cells.
    Smit DJ; Brauer H; Horn S; Yigit G; Haider MT; Pogenberg V; Schumacher U; Pantel K; Jücker M
    Cell Signal; 2024 Sep; 121():111270. PubMed ID: 38909932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
    Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
    Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resveratrol potentiates the anti-tumor effects of rapamycin in papillary thyroid cancer: PI3K/AKT/mTOR pathway involved.
    Bian P; Hu W; Liu C; Li L
    Arch Biochem Biophys; 2020 Aug; 689():108461. PubMed ID: 32531316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin II enhances the proliferation of Natural Killer/T-cell lymphoma cells via activating PI3K/Akt signaling pathway.
    Zhang GH; Miao FA; Xu JG; Zhang Y
    Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 32969473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of metformin on the PI3K/AKT/FOXO1 pathway in anaplastic thyroid Cancer cell lines.
    Nozhat Z; Mohammadi-Yeganeh S; Azizi F; Zarkesh M; Hedayati M
    Daru; 2018 Dec; 26(2):93-103. PubMed ID: 30242671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-Regulation of the Mammalian Target of Rapamycin (mTOR) Pathway Mediates the Effects of the Paeonol-Platinum(II) Complex in Human Thyroid Carcinoma Cells and Mouse SW1736 Tumor Xenografts.
    He L; Guo S; Zhu T; Chen C; Xu K
    Med Sci Monit; 2020 Jun; 26():e922561. PubMed ID: 32594094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
    Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
    Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Synergistic Anti-colon Cancer Effect of Aurora A Inhibitors and AKT Inhibitors Through PI3K/AKT Pathway.
    Sun C; Qu Z; Liu W; Qiu Z; Lü Y; Sun Z
    Anticancer Agents Med Chem; 2023; 23(1):87-93. PubMed ID: 35466883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Targeting of AKT and mTOR Synergistically Inhibits Formation of Primary Colorectal Carcinoma Tumouroids
    Nörz D; Mullins CS; Smit DJ; Linnebacher M; Hagel G; Mirdogan A; Siekiera J; Ehm P; Izbicki JR; Block A; Thastrup O; Jücker M
    Anticancer Res; 2021 May; 41(5):2257-2275. PubMed ID: 33952452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-1246 regulates the PI3K/AKT signaling pathway by targeting PIK3AP1 and inhibits thyroid cancer cell proliferation and tumor growth.
    Li J; Zhang Z; Hu J; Wan X; Huang W; Zhang H; Jiang N
    Mol Cell Biochem; 2022 Mar; 477(3):649-661. PubMed ID: 34870753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition.
    Atanasova VS; Riedl A; Strobl M; Flandorfer J; Unterleuthner D; Weindorfer C; Neuhold P; Stang S; Hengstschläger M; Bergmann M; Dolznig H
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of silencing CITED1 gene to regulate PI3K/AKT pathway on the biological function of PTC cells and its mechanism.
    Chen W; Yu J; Xie R; Zhang S; Zhou T; Xiong C; Huang D; Zhong M
    Cell Mol Biol (Noisy-le-grand); 2023 Sep; 69(9):113-117. PubMed ID: 37807325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
    Lee JB; Jung M; Beom SH; Kim GM; Kim HR; Choi HJ; Sohn JH; Ahn JB; Rha SY; Chung HC
    Invest New Drugs; 2021 Oct; 39(5):1366-1374. PubMed ID: 33723724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.
    Floc'h N; Kinkade CW; Kobayashi T; Aytes A; Lefebvre C; Mitrofanova A; Cardiff RD; Califano A; Shen MM; Abate-Shen C
    Cancer Res; 2012 Sep; 72(17):4483-93. PubMed ID: 22815528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of esophageal cancer growth through the suppression of PI3K/AKT/mTOR signaling pathway.
    Shi N; Yu H; Chen T
    Onco Targets Ther; 2019; 12():7637-7647. PubMed ID: 31571914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023).
    Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
    Expert Opin Ther Pat; 2024 Mar; 34(3):141-158. PubMed ID: 38557273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.